65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details


臨床試験数 : 482 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03217617
(ClinicalTrials.gov)
July 15, 20173/7/2017Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)Gene Transfer for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)SCID, X LinkedBiological: TYF-IL-2Rg gene-modified autologous stem cellsShenzhen Geno-Immune Medical InstituteNULLRecruiting1 Month10 YearsMale10Phase 1/Phase 2China
2EUCTR2015-003369-27-DE
(EUCTR)
01/07/201618/05/2016A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID)A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID) - REGAIN: REGulatory T cells and Aldesleukin for Immunodeficiency- associated eNteropathy autoimmune enteropathy (AIE) in common variable immunodeficiency (CVID).
MedDRA version: 19.0;Level: PT;Classification code 10021449;Term: Immunodeficiency common variable;System Organ Class: 10021428 - Immune system disorders
MedDRA version: 19.0;Level: LLT;Classification code 10017922;Term: Gastroenteropathy NOS;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: PROLEUKIN® S
Product Name: Aldesleukin
INN or Proposed INN: Aldesleukin
Other descriptive name: ALDESLEUKIN
Universitätsklinikum FreiburgNULLNot RecruitingFemale: yes
Male: yes
6Phase 2Germany
3NCT00774358
(ClinicalTrials.gov)
October 200816/10/2008Interleukin-2 Treatment for Wiskott-Aldrich SyndromeReinstituting Natural Killer Cell Cytotoxicity and Cytoskeletal Dynamics in Wiskott-Aldrich Syndrome With IL-2 TherapyWiskott-Aldrich Syndrome (WAS);X-linked ThrombocytopeniaDrug: Interleukin-2Soma JyonouchiTexas Children's HospitalCompleted24 MonthsN/AAll9Phase 1United States
4NCT00004695
(ClinicalTrials.gov)
September 199724/2/2000Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable ImmunodeficiencyCommon Variable ImmunodeficiencyDrug: PEG-interleukin-2Mount Sinai School of MedicineNULLCompleted2 YearsN/ABoth48N/ANULL